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Summary SDZ 280-446 is a semi-synthetic derivative of a natural cyclic peptolide. Its ability to sensitise in
vitro tumour cells whose resistance is due to P-glycoprotein-mediated anticancer-drug efflux was shown using
four different pairs of parental drug-sensitive (Par-) and multidrug-resistant (MDR-) cell lines, from three
different species (mouse, human, Chinese hamster) representing four different cell lineages (monocytic leu-
kaemia, nasopharyngeal epithelial carcinoma, colon epithelial carcinoma, ovary fibroblastoid carcinoma), and
using four different drug classes (colchicine, vincristine, daunomycin/doxorubicin and etoposide). By measur-
ing its capacity to restore normal drug sensitivity of MDR-cells in culture in vitro, it appeared that SDZ
280-446 belongs to the same class of very potent chemosensitisers as the cyclosporin derivative SDZ PSC 833:
both are about one order of magnitude more active than cyclosporin A (CsA), which is itself about one order
of magnitude more active than other known chemosensitisers (including verapamil, quinidine and amiodarone
which have already entered clinical trials in MDR reversal). Low concentrations of SDZ 280-446 could also
restore cellular daunomycin retention in MDR-P388 cells to the levels found in the Par-P388 cells. SDZ
280-446 was also effective as a chemosensitiser when given orally in vivo. In a syngeneic mouse model,
combined therapy with vinca alkaloids given i.p. and SDZ 280-446 given per os for 5 consecutive days
significantly prolonged the survival of MDR-P388 tumour-bearing mice, when compared with mice receiving
vinca alkaloids alone. Another protocol, using three cycles of i.p. doxorubicin at 4 day intervals, could also
not increase MDR-P388 tumour-bearing mouse survival unless the mice received SDZ 280-446 orally 4h
before each doxorubicin injection. Though only very few combined therapy treatment protocols have been
tested so far, clear increases in survival time of MDR-tumour-bearing mice were regularly obtained, leaving
hope for major improvement of the therapy using other dosing schedules.
One of the major causes of therapeutic failure in cancer is the
presence of intrinsically anticancer drug (ACD) resistant cells
and/or to the emergence of resistant clones after repeated
courses of chemotherapy. This problem is further exacerbat-
ed by the observation that these emerging tumours are often
cross-resistant to other chemotherapeutic agents, even though
these drugs were not used in the initial treatment, belong to
unrelated structural classes and have different mechanisms of
action. This phenomenon is widely known as 'multidrug-
resistance' (MDR) (Bellamy et al., 1990; Moscow & Cowan,
1990).
A common mechanism by which tumour cells acquire
MDR is the overexpression of a particular class of trans-
membrane glycoprotein, encoded by a small family of mdr
genes and called the P-glycoprotein (Pgp). By rapidly pump-
ing the ACD out of the MDR-tumour cells, Pgp molecules
decrease the intracellular ACD concentration below its active
(cytostatic) threshold. In vitro, it is possible to overcome this
ACD-escape mechanism of MDR-cells by increasing the
ACD concentration in the culture medium (Bradley et al.,
1988; Endicott & Ling, 1989; Juranka et al., 1989). However,
this cannot be done in vivo since in clinical practice, cancer
patient treatments are already performed with ACD regimens
close to the maximal tolerated dose (MTD). As a conse-
quence, MDR-tumours cannot be treated by some of the
most effective ACD available today, since the doses required
to reach cytostatic levels are unacceptably toxic if not lethal
to the patient (Bellamy et al., 1990; Moscow & Cowan,
1990).
Several studies have allowed the identification of a variety
of agents which, in vitro, can decrease the ACD-resistance of
MDR-tumour cells and sometimes completely restore their
normal sensitivity to chemotherapeutic agents (Twentyman,
1988; Zamora et al., 1988; Ford et al., 1989; Georges et al.,
1990; Hofsy & Nissen-Meyer, 1990). Such chemosensitisers
or 'Resistance-modulating' (RM) agents (RMA) belong to a
variety of structural classes, though a high hydrophobicity
and an ability to diffuse through the cell membrane seem to
be common requirements. They seem to act by blocking the
effluxing-function of Pgp, although this has not been
conclusively shown in each case. Thus this functional neut-
ralisation of the pump-causing MDR restores the normal
accumulation and distribution of ACDs within the MDR-
tumour cells and therefore their sensitivity (Bradley et al.,
1988; Endicott & Ling, 1989; Juranka et al., 1989; Georges et
al., 1990).
Early reports indicated the RM-activity of cyclosporin A
(CsA; SandimmuneTM [Twentyman, 1988]) seemed to be in
vitro an order of magnitude higher than the RM-activity of
several other RMAs such as verapamil, amiodarone and
quinidine (Boesch et al., 1991a), which have already entered
clinical trials. Cyclosporin research has generated over a
number of years a large family of related molecules in order
to find compounds with improved immunosuppressive speci-
ficity and decreased host-toxicity. Their screening for RM-
activity allowed us (Gaveriaux et al., 1989) to clearly separate
the two known properties of the cyclosporin molecule, i.e. its
immunosuppressive activity, possibly mediated through its
interaction with cyclophilin (Takahashi et al., 1989), and its
MDR-reversing activity, possibly mediated through its inter-
action with Pgp (Foxwell et al., 1989) and led to the identi-
fication of SDZ PSC 833, a cyclosporin derivative endowed
in vitro with the near maximally achievable MDR-reversing
potency (Gaveriaux et al., 1991). It is an order of magnitude
more active than CsA to normalise the ACD-dependent
growth inhibition of several MDR-tumour cell lines (Gave-
riaux et al., 1991). In vitro, at sub-micromolar concentra-
tions, this RMA is capable of restoring to normal levels the
intracellular ACD retention of MDR-tumour cells (Boesch et
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al., 1991b). It is also active in vivo (Boesch et al., 1991c),
being able to restore chemotherapeutic responses of MDR-
tumour cells whose degree of resistance is much higher than
that known to occur in cancer patients.
In parallel to our work on cyclosporins, a series of semi-
synthetic derivatives of the cyclic peptolide SDZ 90-215
which had been isolated initially as an antifungal agent from
the fermentation broth of a strain of the Fungi imperfecti
class (genus Septoria sp.) were studied for RM-activity, and a
set of compounds was identified which showed high potency.
From these, SDZ 280-446 was selected for further evaluation.
We now report on the properties of SDZ 280-446 whose
outstanding RM-activity is of the same order of magnitude,
both in vitro and in vivo, as SDZ PSC 833 with which it
shares no primary sequence homology.
Materials and methods
Drugs
For in vitro experiments, colchicine (COL, Sandoz), vincris-
tine (VCR, vincristine sulfate, Serva, Heidelberg), dauno-
mycin (DAU, Sigma, St Louis, Mo) and doxorubicin (DOX,
Sigma) were prepared as stock solutions in culture medium,
whereas vinblastine (VBL, vinblastine sulfate, Janssen
Chimica) and etoposide (VP-16, Sandoz) were prepared in
dimethylsulfoxide (DMSO). Verapamil (Ver, Sigma), CsA
(Sandoz), SDZ PSC 833 (Sandoz) and SDZ 280-446 (Sandoz)
were prepared as stock solutions in absolute ethanol as des-
cribed (Gaveriaux et al., 1991).
For in vivo experiments, the RMAs (CsA and SDZ 280-
466) were dissolved at 10mgml1l in either olive oil or corn
oil containing 165 mg ml1 ethanol and 385 mg ml' Labrafil
(Sandoz, Basel). VCR, VBL and DOX solutions for i.p.
injections were prepared as described (Boesch et al., 1991c).
Tumour cell lines
The cell lines belonged to three species and four cell classes
covering all levels of adherence from none to very strong: the
murine monocytic leukaemia P388N (Par-) and P388DoXR
(MDR-), the Chinese hamster ovary (CHO) fibroblastoid
carcinoma AUXB1 subclone ABlSII (Par-) and CHRC5 sub-
clone C5S3.2 (MDR-), the human colon epithelial carcinoma
LoVo (Par-) and LoVo/Dx (MDR-) and the human naso-
pharyngeal carcinoma KB-3-1 (Par-) and KB-V1 (MDR-).
All MDR-cell lines were continuously grown in the pre-
sence of the drug used for their selection; 8 to 24 h before
each experiment the culture medium of the MDR-cell lines
was removed and the cells were grown in drug-free medium.
The origins and detailed conditions for in vitro growth and
analyses of these eight different cell lines were as published
earlier (Gaveriaux et al., 1991).
In vitro cytotoxicity studies
Tumour cell growth and its drug-mediated inhibition were
measured as described previously (Gaveriaux et al., 1989,
1991; Boesch et al., 1991a). The growth levels obtained with-
out RMA and ACD, but with their solvents were taken as
representing 100% growth. The ACD IC50s (Table I) were
calculated from the dose-response curves obtained by plot-
ting the measured growth vs the ACD concentration as
described previously (Gaveriaux et al., 1989). Cultures per-
formed in absence ofACD (but in the presence of its solvent)
with the whole range of RMA concentrations allowed the
construction of (RMA dose/cell growth response) curves and
the determination of the RMA IC50s (Table I) (Boesch et al.,
1991a; Gaveriaux et al., 1991). In chemosensitisation assays,
only RMA concentrations giving less than 10-20% growth
inhibition of the particular cell line were considered to give
significant results. A complete [ACD dose/cell growth re-
sponse] curve was constructed at each RMA concentration.
A whole range of 'IC50+' values were thus obtained in the
presence of the whole range of tested RMA (Ver, CsA, PSC)
concentrations, the 'IC50-' values being obtained in the
absence of RMA (but in the presence of its solvent). The
increases of ACD sensitivity or 'gains' in sensitivity of the
RMA-treated cells were given by the ratio [IC50-/IC50+]
and a gain was calculated for each RMA concentration
(Gaveriaux et al., 1991).
Intracellularfluorescence studiesfor DAU retention
They were performed in parallel with studies on the activity
of SDZ PSC 833 and of a variety of other RMAs to restore
DAU retention in MDR-P388 cells (see [Boesch et al., 1991b]
for methodological procedures).
Briefly, samples of 10' cells were incubated in a 7.5% CO2
humidified atmosphere at 37°C for 30 min in 2 ml medium
containing 20 fLM DAU in absence or presence of RMA
(DAU-uptake phase). The DAU excess not taken up or not
retained by the cells was removed as follows: the cells were
first centrifuged at 200 g at 4°C, resuspended in 2 ml of
drug-free medium (lacking both DAU and RMA) and rein-
cubated for 15 min at 37°C (DAU-release phase). After two
further washes by centrifugation and resuspension in DAU-
and RMA-free medium, the cells were fixed in 1 ml of PBS-
3.7% formaldehyde and analysed for intracellular DAU fluo-
rescence with a FACScan cell analyser (Becton Dickinson,
Mountainview, CA) equipped with an argon laser (15 mW)
tuned at 488 nm. Dead cells and debris were excluded by
setting a gate on the basis of their decreased forward light
scatter. Fluorescence histograms were obtained with the fluo-
rescence channels on the X-axis and the numbers of cells on
the Y-axis (see [Boesch et al., 1991b] for details). In order to
facilitate the comparison of the effects of the RMAs on the
fluorescence levels of Par-P388 and MDR-P388 cells, the
peak fluorescence levels (Y-axes) were plotted vs the RMA
concentrations (X-axes) in the diagrams shown in this paper.
Table I ACD and RMA IC501 (as ugml') for the different tumour cell lines
Cell line ACD IC50 RMA IC50
COL VCR DAU VP-16 CsA SDZ PSC833 SDZ 280-446
M.W. 1206.6 1214.65 1182.6
Par-CHO 0.044±0.010 0.059±0.019 0.021±0.006 0.128±0.016 7.8 4.0 16.0
MDR-CHO 2.5±0.7 1.6±0.4 1.7±0.2 5.2± 1.5 24.5 3.9 17.2
Par-KB 0.003±0.0007 0.0027± 0.001 0.18±0.08 2.1±1.4 15.8 71.0 42.0
MDR-KB 1.5±0.3 10.9±0.3 6.4±1.1 55.1±15.1 > 100 22.0 25.5
Par-P388 0.0042±0.0008 0.007±0.0029 0.011 ±0.004 0.11 ± 0.04 0.45 2.5 1.9
MDR-P388 0.52±0.03 1.2±0.3 1.7±0.1 16.7±3.3 1.35 5.9 7.2
Par-LoVo 0.017±0.002 0.072±0.037 0.026±0.001 1.05±0.26 12.0 9.4 13.5
MDR-LoVo 0.41 ±0.032 2.0±0.3 0.75±0.12 13.3± 1.3 15.8 13.5 14.5
aFor all three RMAs, I tLgml- ±0.8fM. The concentrations ofACDs giving 50% inhibition ofcell growth in vitro were the
means±standard deviations ofindividual determinations performed over more than 2 years. The IC50 values reported for RMAs
were calculated from the mean dose/response curves. With DOX, the IC50s were 0.03±0.01 ;Lg ml- I for the Par-P388 cell line: and
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In vivo studies
They were performed in parallel to our in vivo studies of
SDZ PSC 833 (Boesch et al., 1991c), i.e. based on standard
NCl protocols for screening new ACDs (Kallman, 1987) and
adapted for studying RMA activity in mice bearing a moder-
ately resistant MDR-P388 tumour (Tsuruo et al., 1981; Shi-
noda et al., 1989).
Briefly, female 6-8 week-old DBA/2 mice or B6D2F1
hybrid mice (IFFA-CREDO, 69210 L'Arbresle, France) were
used as recipients for syngeneic grafts of leukaemic P388
cells. In life monitoring was restricted to daily body weight
measurement, examination of ascites development and re-
cording of time of death. One or five million tumour cells
were inoculated i.p. on 'day 0' at 0 time. The RMAs were
given to the mice by gavage per os, as a function of mouse
weight, at various times according to the different protocols.
Control mice received the same volume of the vehicle only as
placebo. The ACDs were given as a function of mouse
weight, either injected i.p. for VCR, VBL and DOX, or given
by gavage per os for VP-16; control mice received the vehicle
only as placebo.
The mean survival times (MST) were recorded following
various drug treatment protocols. To represent the variablity
of response within an experimental group, an index of indivi-
dual variability (I.V.) was used and calculated like a standard
deviation of the mean of the values obtained with the indivi-
dual mice of the group as if there were several values deter-
mined independently for measurement of a single individual
mouse.
In the different groups the MST were compared at T/C
ratios (%) that is the ratio of survival time (in days) for
treated mice (T) to untreated control mice (C). The signi-
ficance of the survival data of drug-treated groups vs untreat-
ed groups or ofcombined vs single therapy were evaluated by
'P' values (student's t-test, unpaired data) (for further details,
see Boesch et al., 1991c).
Results
SDZ 280-446 selection
SDZ 280-446 (Figure 1), the chemistry of which will be
reported in a separate publication (G. Emmer et al., in
preparation), was one of a series of semi-synthetic and non-
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Figure 1 Structure of SDZ 280-446. SDZ 280-446 is cyclo-[Pec' -
MeVal2
- Val3 - (-O-t.Bu-MeAsp4) - Melles Melle6 - Gly7 -
MeVal8 - (O-MeTyr9) - L-Hpall; empirical formula C61H99N9014,
Molecular Weight: 1182.6.
immunosuppressive derivatives of SDZ 90-215, a natural cyc-
lic peptolide isolated from a Fungus imperfecti (Septoria sp.,
Sandoz strain F/42508). It selection was performed through
the same screening systems that led to the selection of SDZ
PSC 833 (Gaveriaux et al., 1991), using four pairs of Par-
and MDR-tumour cell lines, searching for a broad 'in vitro
therapeutic window', i.e. the lowest possible intrinsic cyto-
static activity together with the highest possible chemosen-
sitising activity.
All MDR-cell lines were variants with high expression of
Pgp/mdrl mRNA and indeed displaying a high level of
MDR against several ACDs, particularly COL, VCR, VP-16
and DAU and/or DOX (Table I). The Par-P388 and Par-KB
cell lines showed minimal IC50s for these agents, did not
express detectable amounts of Pgp or mdrl mRNA and were
not chemosensitisable by any of our RMAs known or sus-
pected to work through inhibition of Pgp function. However
the Par-CHO and Par-LoVo cell lines which expressed small
but detectable amounts of Pgp or mdrl mRNA could be
sensitised by micromolar concentrations of weak RMAs or
by sub-micromolar concentrations of strong RMAs.
These four pairs of cell lines also showed variable sen-
sitivity (IC50) to the RMAs (Table I). However there was no
rule regarding the relative resistance of the Par- and MDR-
cell variants for ACDs and for RMAs, nor regarding the
intrinsic growth inhibition capacity of the RMAs. For in-
stance, CsA was the most cytostatic RMA for Par-P388 cells
and the least cytostatic RMA for MDR-KB cells, while SDZ
PSC 833 was more cytostatic for MDR-KB cells than for
Par-KB cells, that SDZ 280-446 IC50s were roughly similar
for the growth inhibition of both sublines of CHO and LoVo
cells, and so on. Though this is shown here for three RMAs
and four cell line pairs only, our experience with several
other RMAs and a few other cell lines does not suggest that
there is a correlation between resistance to the ACD and
resistance to the RMA, at least within the Pgp-mediated
resistance context.
In vitro restoration ofACD-sensitivity: RM-strengths ofSDZ
280-446, SDZ PSC 833 and CsA
The sensitising capacity of the RMAs for various ACDs was
studied as a function of the RMA concentration (for all three
RMAs, llAM= ± 1.2jg ml-' or Ilg ml = ± 0.8pM) and
represented as isobolic curves (one per ACD and RMA
combination). These isobolograms give the RMA concentra-
tions on the X-axes and the ACD sensitivity gains on the
Y-axes. Each gain is defined as the ratio of ACD [IC50-/
IC50+] determined from ACD dose/response curves perform-
ed in absence (IC50-) or presence (IC50+) of RMA. Such
isobolograms thus express the sensitising capacity of the
RMAs for various ACDs as a function of the doses of
RMAs.
The isobolograms shown in Figures 2-5 indicate that SDZ
280-446 (M.W. 1182.6) is about equipotent as RMA with
SDZ PSC 833 (M.W. 1214.65) but much more potent than
CsA (1206.6). Throughout all RMA, ACD and MDR-cell
line combinations, it is apparent that equimolar concentra-
tions of SDZ 280-446 and SDZ PSC 833 gave a stronger
chemosensitisation (larger 'gains') than CsA; or, similarly,
that equivalent chemosensitisation (similar 'gains') required
lower concentrations of SDZ 280-446 and SDZ PSC 833
than of CsA. A simplified, yet less complete picture, is
obtained by comparing the doses of RMA giving similar
gains in sensitivity (e.g. a 10 fold gain, where achievable, as
shown in Table II, which also includes verapamil (M.W. 491)
for comparison).
As already found with SDZ PSC 833, a complete reversion
of the resistance of the MDR cells (i.e. a gain in sensitivity
equal to the relative resistance between the Par- and MDR-
cell lines) could be obtained with the CHO, P388 and LoVo
MDR cells, but not with the available variant of MDR-KB
cells. The latter were however significantly sensitisable by
SDZ 280-446, as well as by SDZ PSC 833 though not by
CsA.14 F. LOOR et al.
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Figure 2 Chemosensitisation of CHO cells in vitro by SDZ
280-446, SDZ PSC 833 and CsA. Par-cells (open symbols) and
MDR-cells (closed symbols) were cultured with ranges ofconcen-
trations of colchicine, daunomycin, etoposide or vincristine
together with a range of concentrations of SDZ 280-446 (M.W.
1182.6; 0 *), SDZ PCS 833 (M.W. 1214.65; A A) or CsA
(M.W. 1206.6; 0 *) (X-axes). The ratios of ACD IC50s obtain-
ed in the absence of RMA and in the presence of each RMA
concentration, i.e. the gains of sensitivity are recorded on the
Y-axes. Each gain was determined from two individual ACD
dose-cell growth inhibition curves at inactive or hyperactive
RMA concentrations up to nine such determinations for mid-
active RMA concentrations.
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Figure 4 Chemosensitisation of P388 cells in vitro by SDZ 280-
446, SDZ PSC 833 and CsA. Same representation as in Figure 2.
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Figure 3 Chemosensisation of KB cells in vitro by SDZ 280-446,
SDZ PSC 833 and CsA. Same representation as in Figure 2.
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Figure 5 Chemosensisation of LoVo cells in vitro by SDZ 280-
446, SDZ PSC 833 and CsA. Same representation as in Figure 2.
Though the highest gains in sensitivity to ACDs were
obtained with the MDR cells, significant gains were also
found with cells from two Par-cell lines (CHO and LoVo).
The latter Par-cells actually express small amounts of Pgp
and thus are susceptible to chemosensitisation. On the con-
trary the two Par-cell lines which do not detectably express
Pgp (Par-KB and Par-P388) were not chemosensitisable to
any significant extent.
Particularly with the most potent RMAs, the chemosensi-
tising activity was quite distinct from the negligible growth
inhibitory effects of the RMAs themselves. For example, with
MDR-P388 cells, 10-fold gains were obtained with less than
0.1 jg ml-' (less than 0.08tLM) SDZ PSC 833 or SDZ 280-
446 (Table II), while the IC50s for these RMAs were 6-7 ytg
ml-' (Table I). Similarly with MDR-LoVo cells, about
0.2 lLM SDZ PSC 833 or 0.4 liM SDZ 280-446 gave 10-fold
gains (Table II), while the IC50s of both RMAs reached
about 15 tM (I3.5-14.5lAgml-') (Table I).
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Table II RMA molarities giving either a 10-fold GAIN ( = degree ofchemosensitisation) or themaximal
achievable GAIN of sensitivity
Verapamil CsA SDZ PSC833 SDZ 280-446
Cell lines ACD Gain tM Gain AM Gain JiM Gain JiM
Par-CHO COL 9.1 50 8.9 1.67 10 0.29 9.5 4.2
VCR 10 5.7 10 0.63 10 0.023 10 0.091
DAU 10 34 7.4 4.2 10 0.39 8.1 4.2
VP-16 4.8 30 8.3 2.5 7.1 0.82 6.7 4.2
MDR-CHO COL 10 6.4 10 0.37 10 0.017 10 0.013
VCR 10 2.8 10 0.50 10 0.025 10 0.013
DAU 10 1.5 10 0.35 10 0.011 10 0.009
VP-16 10 12.3 10 0.50 10 0.017 10 0.016
Par-LoVo COL ND 3.7 8.3 4.8 2.5 4.9 2.5
VCR ND 3.7 8.3 10 0.034 10 0.12
DAU ND 4.3 2.5 3.8 1.6 4.3 4.2
VP-16 ND 4.7 2.5 2.7 1.6 2.8 2.5
MDR-LoVo COL ND 10 2.68 10 0.21 10 0.28
VCR ND 10 1.0 10 0.26 10 0.38
DAU ND 10 1.77 10 0.15 10 0.57
VP-16 ND 10 2.50 10 0.25 10 0.44
MDR-P388 COL 10 11.7 10 0.32 10 0.070 10 0.061
VCR 10 3.1 10 0.27 10 0.033 10 0.040
DAU 10 3.3 10 0.30 10 0.045 10 0.068
DOX 10 3.9 10 0.3 10 0.034 10 0.059
VP-16 10 11.4 10 0.21 10 0.026 10 0.076
MDR-KB COL 10 11.8 1.9 2.5 10 0.86 10 0.57
VCR 10 3.1 1.7 4.2 10 0.86 10 0.71
DAU 10 10.5 4.7 4.2 10 0.84 10 0.83
VP-16 3.5 30 1.1 4.2 10 1.89 10 0.93
Restoration ofDAU retention in MDR-P388 cells by CsA,
SDZ PSC 833 and SDZ 280-446
The intracellular ACD retention was measured by the degree
of anthracycline-fluorescence of the P388 cells of both Par-
and MDR-lines following in vitro exposure to DAU, either
with the fluorescence-microscope (end point active concentra-
tion) or with a FASC (more quantitative data). While Par-
P388 cells displayed a high nuclear fluorescence upon in vitro
exposure to DAU, and MDR-P388 cells did not fluoresce at
all, indicating the low intracellular DAU content. In fluore-
scence studies, the bright nuclear fluorescence of Par-P388
cells was identical whether they had been exposed to the
RMA or not. In contrast, there was a RMA dose-dependent
increase in the degree of nuclear fluorescence of the MDR-
P388 cells. In order to reach a similar fluorescence intensity
(almost as bright as the fluorescence displayed by the Par-
P388 cells) the MDR-P388 cells had to be exposed to 10-30
Lg ml-' CsA, 1-3tLgml-' SDZ 280-446 or 0.3-1.0tgml-'
SDZ PSC 833. Both SDZ PSC 833 and SDZ 280-446 at
30 jLg ml-' allowed a complete restoration of the DAU reten-
tion by the MDR-P388 cells, whereas CsA could not (not
shown).
Though they did not allow distinction of the 'specific', i.e.
nuclear, fluorescence from the whole cell fluorescence, flow
cytometry analyses of DAU retention in Par-P388 and
MDR-P388 cells provided less subjective comparison of the
DAU retention in the two cell lines as a function of the
RMA concentration. In the absence of RMA treatment, the
MDR-P388 cells displayed low fluorescence levels corre-
sponding to 4.5-5.8% of the Par-P388 cell fluorescence
levels. Definite shifts of the fluorescence profiles of the RMA-
treated MDR-P388 cell populations were observed at low
concentrations of all three RMAs. As already described for
several other RMAs (Boesch et al., 1991b), these shifts were
obtained at different concentrations and showed subtle differ-
ences for the different RMAs.
In order to facilitate the comparison of the effects of the
RMAs on the fluorescence levels of Par-P388 and MDR-
P388 cells, the peak fluorescence levels (Y-axes) were plotted
vs the RMA concentrations (X-axes) in Figure 6 which com-
pares SDZ PSC 833 and SDZ 280-446 with CsA. The lowest
RMA concentrations sufficient to restore fully DAU reten-
tion in MDR-P388 cells were 30 fig ml' for CsA, 1-3 fg
ml-' for SDZ PSC 833 and 3-10gml-' for SDZ 280-446.
Therefore, by measuring the short term, RMA-mediated inhi-
bition of Pgp function, SDZ PSC 833 was found to be about
three times more active than SDZ 280-446 and 10-30 times
more active than CsA.
In vivo efficacy ofSDZ 280-446
Vinca alkaloids (VCR or VBL) as ACD Although they
could prolong the survival of mice bearing the Par-P388
tumour cells, neither VCR nor VBL alone could significantly
prolong the survival of MDR-P388 cell-grafted mice up to
the high ACD dosages where they became severely toxic for
the mice themselves (i.e. toxic for tumour-free mice) (Boesch
et al., 1991c).
Four independent experiments using vinca alkaloids allow-
ed to evaluate the chemosensitising efficacy of SDZ 280-446
(Table III). In all four experiments DBA/2 mice were grafted
at Day 0 with five millions (parts A and B) or one million
(parts C and D) Par-P388 or MDR-P388 tumour cells. Then,
the RMA or its placebo was given by gavage per os and the
vinca alkaloid was injected i.p. for 5 consecutive days.
The vinca alkaloids alone in the 15-100 igkg-' daily
dosage range could not significantly prolong the survival of
the mice bearing a MDR-tumour and were variably effective
for mice grafted with Par-tumour cells. The daily treatment
with 100 mg kg-' of SDZ 280-446 alone had also no signi-
ficant effects on the survival of tumour-bearing mice. In
contrast the vinca alkaloids could significantly increase, the
survival of the MDR-tumour-bearing mice when administer-
ed i.p. together with SDZ 280-446 per os. The effect of SDZ
280-446 was dose-dependent, the 100 mg kg-' daily dosage
appearing to be most effective for this treatment protocol.
Curiously enough mice bearing Par-tumour and treated by
the combined therapy could also show increased survival in
comparison with mice treated with vinca alkaloid alone.
Though this may be accounted for by an increased bioavail-
ability of ACD when used in combination with SDZ 280-446,
it would not suffice to explain the higher efficacy of vinca
alkaloids on the MDR-tumour: as mentioned earlier it was
not possible to interfere with MDR-tumour growth-mediated
mouse death by increasing the daily dosage of vinca alkaloids
up to the doses which were severely toxic for tumour-free
mice.16 F. LOOR et al.
1000
SIM
100 -
10 d/I 1ititi iii1i 1 iiiiil III ,
a)
0)
C.)
c
0)
0.)
c
4-
C.)
0
0
C-
10 100
1000 =
SDZ PSC 833
100 _
10 tv """tii 11111fi 11111111
iii,l 1IIIIII
0 0.01 0.1 1 10 100
0.01 0.1 1 10 100
Concentration (,uM)
Figure 6 Effect of the RMAs on the DAU-retention by Par-
P388 (0) and MDR-P388 (0) cells. SDZ PSC 833 and SDZ
280-446 were compared with CsA ("SIM"). The cells were
incubated for 30 min at 37°C with 20 gM DAU and a range of
RMA concentrations. After washing the cells were incubated in
DAU- or RMA-free medium at 37C. The fluorescence measured
by flow cytometry was represented on a logarithmic scale. The
peak fluorescence levels (Y-axes) are shown vs the RMA concen-
trations (X-axes).
Topoisomerase II inhibitor (DOX) as ACD
Previous experiments indicated that treatment with DOX i.p.
three times at 4 day intervals starting on day 1 after tumour
inoculation achieved a significant prolongation of survival of
Par-P388 tumour-bearing mice, but not of MDR-tumour-
bearing mice. However a pre-treatment with SDZ PSC 833
24 h before each DOX administration (2 mg kg-' i.p.) could
clearly increase the survival of MDR-P388 tumour-bearing
mice (T/C of about 170%). When SDZ PSC 833 pharmaco-
kinetics could be taken into account, the time between SDZ
PSC 833 p.o. and DOX i.p. was then reduced to 4 h and the
SDZ PSC 833 dose was reduced to 50 or 25 mg kg-'; this
dramatically improved the efficacy of the combined chemo-
therapy (Boesch et al., 1991c).
Though pharmacokinetic information on SDZ 280-446 was
lacking, a similar treatment protocol was assayed. Thus the
tumour cells were injected i.p. at day 0 (4 h before 0 time),
SDZ 280-446 or its vehicle was given p.o. at days 0, 4 and 8,
and DOX or its vehicle was injected i.p. 4 h after each
gavage with the RMA. The data of one complete experiment
are shown in Table IV. As expected, the treatment with DOX
alone did not result in increased mouse survival (MST of
13.6 instead of 12.8 days). Similarly, no remarkable effects on
mouse survival were observed in the groups treated with
SDZ 280-446 alone. However, a highly significant prolonga-
tion of the survival of the MDR-P388 tumour-bearing mice
was obtained by the combined therapy: with SDZ 280-446 (at
25 and 50 mg kg-' given 4 h before each DOX treatment),
the mouse survival reached about 31 days, the combined
therapy being thus roughly 2-3 fold more effective than the
single DOX therapy.
Discussion
The ability of the cyclic peptolide SDZ 280-446 to sensitise in
vitro tumour cells whose resistance is due to Pgp-mediated
ACD efflux has been well documented for four different pairs
of Par- and MDR-cell lines, from three different species
Table III In vivochemosensitising activityofSDZ280-446forvincaalkaloidsinPar-P388 and MDR-P388
tumour-bearing DBA/2 mice
Chemotherapy Parental-P388 tumour MDR-P388 tumour
SDZ 280-446 ACD MST±IV TIC MST±IV TIC
p.o. (mg kg-') i.p. (.Igkg-') days (n) 'P' (%) days (n) 'P' (%)
Part A a
V V 22.4±0.5 (9) 100 8.1±1.3 (9) 100
V VCR, 100 22.0±5.1 (8) 0.8 98 8.4±1.2 (9) 0.58 104
100 V 24.2±2.8 (6) 0.089 108 7.8±0.5 (5) 0.61 96
100 VCR, 100 35.5±9.7 (4) 0.001 158 12.5±1.8 (10) <0.001 154
Part Ba
V V 20.3±0.5 (7) 100 7.7± 1.5 (7) 100
V VBL, 100 27.1±1.8 (7) <0.001 133 8.4±1.0 (7) 0.31 109
100 V 20.2±0.4 (5) 0.76 100 7.0±0.0 (5) 0.32 91
100 VBL, 30 30.1±2.3 (7) <0.001 148 24.5±3.9 (8) <0.001 318
Part Ca
V V 21.0±3.8 (8) 100 10.7±1.4 (8) 100
V VBL, 100 25.8±7.4 (8) 0.13 123 11.4±1.6 (8) 0.42 107
100 V 22.6± 1.3 (8) 0.27 108 10.3± 1.5 (6) 0.61 96
100 VBL, 30 35.9± 6.2 (7) <0.001 171 19.6± 5.6 (9) 0.001 183
50 VBL, 30 N.D. 12.5±1.5 (10) 0.021 117
25 VBL, 30 N.D. 11.2± 1.0 (9) 0.44 105
12 VBL, 30 N.D. 10.0±1.3 (10) 0.27 93
Part Da
V V 21.6± 1.6 (10) 100 10.4± 1.6 (10) 100
V VBL, 100 26.5±3.6 (6) 0.019 123 9.1±0.4 (7) 0.042 87
V VBL, 30 21.6±1.9 (8) 1.0 100 N.D.
100 V 23.5±4.0 (6) 0.31 109 9.5±0.4 (6) 0.45 91
100 VBL, 30 28.0±4.1 (6) 0.011 130 16.6±2.7 (8) 0.001 160
100 VBL, 15 N.D. 15.9±3.1 (8) 0.001 153
aParts A, B, C & D represent independent experiments. Grafted tumourcells: 5 x 106(parts A& B) or 106
cells (parts C &D). Drug(s) administered at days 0, 2 & 4 (part A) orat days 0, 1, 2, 3 &4 (parts B, C & D).
V = vehicle, (n) = number ofmice.
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Table IV In vivo activity ofthreecycles ofSDZ 280-446 p.o.4 hbefore
DOX i.p. at 4 day intervals for MDR-P388 tumour-bearing B6D2F1
mice
Chemotherapy MDR-P388 tumour
SDZ 280-446a DOX MST±IV TIC
p.o. (mgkg-') ip. (mgkg-') days 'P' (%)
V V 12.8± 2.1 0.074 100
V 2 13.6± 0.9 0.006 106
25 V 12.8± 1.3 0.140 100
50 V 14.2± 1.2 0.002 111
25 2 31.1±11.9 0.002 243
50 2 31.3± 5.1 <0.001 245
'SDZ 280-446 was administered per os 4 h before DOX to MDR-
P388 tumour-bearing B6D2F1 mice (5-8 mice per group); V = vehicle.
(including two human cell line pairs) representing four differ-
ent cell lineages, and using four different ACD classes. It is
clear that SDZ 280-446 and the cyclosporin derivative SDZ
PSC 833 (Gaveriaux et al., 1991; Boesch et al., 1991c)
achieve the same high level of chemosensitisation which is
about one order of magnitude more active than CsA, which
is itself about one order of magnitude higher than other
known chemosensitisers ([Boesch et al., 1991a] including
verapamil, quinidine and amiodarone which have already
entered clinical trials in MDR reversal).
DAU retention could be restored in MDR-P388 cells by
chemosensitisers which bind to the Pgp pump, such as Ver
and CsA. SDZ PSC 833 could restore this retention at lower
doses than CsA which was itself more active than amio-
darone, verapamil, quinidine and all other tested RMAs
(Boesch et al., 1991b). SDZ 280-446 was also identified as
one of the most potent RMA by this assay. The lowest RMA
concentrations sufficient to fully restore DAU retention in
MDR-P388 cells were 30fig ml' for CsA, 1-3 jg ml' for
SDZ PSC 833 and 3-10 tgml-' for SDZ 280-446. There-
fore, by the assay which measures the short term inhibition
of Pgp function by RMA-pretreatment of the MDR-P388
cells, we could evaluate that SDZ PSC 833 was about three
times better than SDZ 280-446 and 10-30 times better than
CsA. In the DAU-growth inhibition assay a 6-fold factor
only was found for the concentrations of CsA (0.30gM) and
SDZ PSC 833 (0.045gM) giving a gain of 10 (Table II); yet
in that assay, SDZ PSC 833 and SDZ 280-446 (0.068gM)
had more similar potencies.
SDZ 280-446 was also effective as a chemosensitiser when
given orally in vivo. In a syngeneic mouse model (P388
tumour cells of DBA/2 origin growing on DBA/2 mice),
combined therapy with vinca alkaloids given i.p. and SDZ
280-446 given per os for 5 consecutive days significantly
prolonged the survival of tumour-bearing mice, when com-
pared with mice receiving vinca alkaloids alone.
This clearly beneficial effect of the combined therapy was
seen principally in recipients of MDR-tumour cells, and not
or only moderately in recipients of Par-tumour cells which
lack resistance. This was similar to what was observed with
SDZ PSC 833 (Boesch et al., 1991c). In the latter case the
effect of the combined therapy on the Par-tumour bearing
recipients could be explained by an increased bioavailability
of the ACD through alterations of the P450 system, as
typical for cyclosporins. Such pharmacokinetic interactions
also occur in the case of SDZ 280-446, but presently avail-
able data are still too fragmentary to allow a comparison
with SDZ PSC 833. Whichever the increased ACD-bioavail-
ability which is beneficial for Par-tumour bearing mice, it
would not be sufficient for the MDR-tumour bearing mice
since it was impossible to obtain any significant prolongation
of survival of MDR-P388 tumour-bearing mice by increasing
the daily dosage of vinca alkaloids (Boesch et al., 1991c).
This clearly shows that the beneficial effect of combining
SDZ 280-446 with a low dose of vinca alkaloid comes essen-
tially from a direct neutralisation of the Pgp which is over-
expressed on MDR-tumour cells by the cyclic peptolide,
rather than indirectly through altering ACD bioavailability.
Although only few treatment protocols with vinca alka-
loids have been tested so far, clear increases in survival times
were regularly obtained, leaving hope for possible improve-
ment of the therapy, using other dosing schedule. Particularly
our results using SDZ 280-446 orally compare well with the
best results reported for a nifedipine analog (AHC-52) given
i.p. with the tumour (Tsuruo et al., 1981; Shinoda et al.,
1989). The superiority of SDZ 280-446 may even be higher
than appears from a simple comparison of the survival in-
creases achieved by SDZ 280-446 and AHC-52 as RMAs.
Indeed in the AHC-52 study two different MDR-P388 cell
lines were used: a P388/VCR which had only a moderate
resistance (12-fold) and a P388/ADR cell line which had a
high resistance (150-fold), in comparison with the Par-P388
line. Combined therapy by AHC-52 and vinca alkaloids had
remarkable effects on the P388/VCR tumour-bearing mice
but showed no efficacy or only marginal effects with mice
bearing the high resistant P388/ADR tumours. Since our
DOX-driven MDR-P388 cell line was actually as highly resis-
tant as the aforementioned P388/ADR line, SDZ 280-446
must be much more potent than AHC-52 in vivo.
All presently available data on the in vivo efficacy of SDZ
280-446 have been obtained by reproducing early SDZ PSC
833-treatment protocols, where the mice were exposed to a
25 times higher cumulative SDZ PSC 833 dosage than in our
later experiments which nevertheless showed much higher
efficacy. It is definite that further improvements of the
efficacy of the SDZ 280-446-aided chemotherapy will be
possible when a better knowledge of its in vivo pharmacology
is available.
Due to the large differences in the pharmacokinetics and
metabolism of MDR-reversing agents and cytostatics in mice
and man, the optimal therapeutic schedule will clearly have
to be established directly on patients, bearing in mind the
possibility of enhanced toxicity with the combination. How-
ever it is highly probable that this would come from the
enhanced bioavailability and effects of the ACD rather than
of intrinsic SDZ 280-446 toxicity, since studies in rats have
shown that SDZ 280-446 is virtually devoid of toxicity when
given orally at doses of 500mg kg-' or more for 2 weeks (P.
Donatsch, Sandoz Toxicology Dept, unpublished data).
Based on the results obtained in vivo it can be anticipated
that SDZ 280-446 given orally shortly prior to and during
cycles of cytostatic therapy could be effective in reversing
resistance of tumours exhibiting MDR to chemotherapy in a
wide variety of patients. Although 25-100mgkg-' of SDZ
280-446 seems to be required in the present protocols to see
a beneficial effect of ACD therapy on the MDR-tumour
bearing mice, all naturally occurring human MDR cancers
are far less resistant than our MDR-tumour cell line models.
Our MDR-P388 cell line is about 100-150 fold more resis-
tant than the Par-P388 cell line. Although it is difficult to
extrapolate from mdrl mRNA levels or Pgp protein levels to
actual resistance degrees, it does not seem that 'naturally-
occurring' MDR cancers will ever show resistance indices
higher than 5-10 (see e.g. Kanamaru et al., 1989). This,
together with the generally higher metabolism rate observed
in small animals, means that our in vivo assays might over-
estimate by an order of magnitude the dosages of RMAs,
such as SDZ 280-446 and SDZ PSC 833, which will be
required in clinical practice.
The mechanisms of action of SDZ PSC 833 and SDZ
280-446 are currently being compared as well as their suit-
ability for in vivo chemosensitisation of MDR-tumour.
Ideally, the RMA should share three properties: (1) the
highest intrinsic RM-activity to allow a complete blockade of
Pgp at low RMA dosages; (2) the largest therapeutic window
of ACD dosages, thus the highest flexibility ofchemotherapy
protocols; and (3) the broadest spectrum of activity towards
most Pgp-mediated tumour types. Whether SDZ PSC 833
might be better in some cases, and SDZ 280-446 in some
other remains an open question.
The authors are very grateful to Drs Maria Grandi, Victor Ling and
Ira Pastan who provided the cell lines used in this study, Kurt
Mueller for help with the FACS analyses, Hans Fliri and Trevor18 F. LOOR et al.
Payne for discussions and for their help in the selection of SDZ
280-446, Peter Hiestand for confirming its lack of immunosuppres-
sive activity, Peter Donatsch for communicating us his preliminary
data on bioavailability and toxicology of SDZ 280-446.
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